Jeffrey A. Cadeddu, MD

Jeffrey A Cadeddu, MD

The University of Texas (UT) Southwestern Medical Center

Dallas, Texas

Dr. Jeffrey A. Cadeddu, MD, is the Ralph C. Smith, MD, Distinguished Chair in Minimally Invasive Urologic Surgery at the University of Texas (UT) Southwestern Medical Center and serves as Director of the UT Southwestern Clinical Center for Minimally Invasive Treatment of Urologic Cancer in Dallas, Texas. He also holds a dual appointment as Professor of Urology and Radiology at UT Southwestern Medical Center. He joined the UT Southwestern Medical Center in 1999 after earning his Doctor of Medicine from Johns Hopkins University School of Medicine in Baltimore, Maryland, where he also completed his urology and surgery residencies. His affiliations include membership in the American Urological Association, the Endourological Society, and the Society for Urologic Oncology. He currently serves as Associate Editor on behalf of the Journal of Endourology, and serves as a Survey Section Editor for the Journal of Urology.

Disclosures:

Talks by Jeffrey A Cadeddu, MD

Mutliparametric MRI for Solid Masses: Accurate Detection of Clear Cell Renal Cell Carcinoma to Direct Patient Care

Posted by Jeffrey A Cadeddu, MD | Oct 2022

Jeffrey A. Cadeddu, MD, Ralph C. Smith, MD, Distinguished Chair in Minimally Invasive Urologic Surgery, Director of The University of Texas (UT) Southwestern Clinical Center for Minimally Invasive Treatment of Urologic Cancer, and Professor of Urology and Radiology at UT Southwestern Medical Center in Dallas, Texas, discusses multiparametric magnetic resonance imaging (mpMRI) for small renal masses (SRM). Dr. Cadeddu emphasizes the use of mpMRI and a clear cell likelihood score (ccLS) as a promising, reliable, non-invasive, and cost-effective means of renal tumor characterization that can eliminate the need for biopsy in most patients.

Kidney Tumor Ablation in 2022: Optimal Outcomes

Posted by Jeffrey A Cadeddu, MD | Jul 2022

Jeffrey A.Cadeddu, MD, discusses optimal outcomes in kidney tumor ablation. He reviews reliable and reproducible 5+ year data comparing ablation effectiveness and outcomes to that of surgery and emphasizes that for tumors of <3 cm, tumor ablation is indicated. Dr. Cadeddu explains that ablation is nephron-preserving and minimizes chronic kidney disease progression, is less expensive than conventional surgery, reduces risk of metastatic potential associated with AS, and in addition to tumor size, histologic subtype is an important consideration in treatment decision-making.